Chinese Clinical Oncology

• 综述与讲座 • Previous Articles     Next Articles

Progress in gastric cancer therapy through targeting VEGF/VEGFR pathway

YU Zijun, HOU Helei, ZHANG Xiaochun   

  1. Department of General Surgery, the No.2 People’s Hospital of Lianyungang, Lianyungang 222006, China
  • Received:2015-11-01 Revised:2016-01-05 Online:2016-06-30 Published:2016-06-30
  • Contact: ZHANG Xiaochun

Abstract: Gastric cancer is one of the most common malignancies in the world. The early diagnosis rate of gastric cancer is low and the efficacy of surgery, radiotherapy and chemotherapy for advanced gastric cancer is limited. Since 1971, Folkman first put forward that the development and metastasis of solid tumors depended on angiogenesis. Targeting tumor angiogenesis has opened a new era in anticancer research. Vascular endothelial growth factor(VEGF) is one of the most potent angiogenic factors which could be secreted by many solid tumors and high VEGF expression is one of the characteristic features of gastric carcinomas. VEGF and its receptor VEGFR played important roles in the occurrence and development of gastric cancer. Therefore, disrupting VEGF/VEGFR signal pathways is considered to be a promising strategy for gastric cancer treatment. This article focuses on the most recent development of the VEGF/VEGFR signal transduction pathways and antiangiogenesis therapy in advanced gastric cancer, especially through targeting VEGF/VEGFR pathway.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!